These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30377559)

  • 21. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
    Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
    Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
    Della Corte CM; Fasano M; Ciaramella V; Cimmino F; Cardnell R; Gay CM; Ramkumar K; Diao L; Di Liello R; Viscardi G; Famiglietti V; Ciardiello D; Martini G; Napolitano S; Tuccillo C; Troiani T; Martinelli E; Wang J; Byers L; Morgillo F; Ciardiello F
    J Exp Clin Cancer Res; 2022 Mar; 41(1):109. PubMed ID: 35346313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
    Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.
    Jochems C; Tritsch SR; Knudson KM; Gameiro SR; Smalley Rumfield C; Pellom ST; Morillon YM; Newman R; Marcus W; Szeto C; Rabizadeh S; Wong HC; Soon-Shiong P; Schlom J
    Oncoimmunology; 2019; 8(2):e1532764. PubMed ID: 30713787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
    Cichocki F; Bjordahl R; Gaidarova S; Mahmood S; Abujarour R; Wang H; Tuininga K; Felices M; Davis ZB; Bendzick L; Clarke R; Stokely L; Rogers P; Ge M; Robinson M; Rezner B; Robbins DL; Lee TT; Kaufman DS; Blazar BR; Valamehr B; Miller JS
    Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
    Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
    Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.
    Bellucci R; Martin A; Bommarito D; Wang K; Hansen SH; Freeman GJ; Ritz J
    Oncoimmunology; 2015 Jun; 4(6):e1008824. PubMed ID: 26155422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
    Stein A; Simnica D; Schultheiß C; Scholz R; Tintelnot J; Gökkurt E; von Wenserski L; Willscher E; Paschold L; Sauer M; Lorenzen S; Riera-Knorrenschild J; Depenbusch R; Ettrich TJ; Dörfel S; Al-Batran SE; Karthaus M; Pelzer U; Waberer L; Hinke A; Bauer M; Massa C; Seliger B; Wickenhauser C; Bokemeyer C; Hegewisch-Becker S; Binder M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34315821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-PD-L1 antibody enhances curative effect of cryoablation
    Tan J; Liu T; Fan W; Wei J; Zhu B; Liu Y; Liu L; Zhang X; Chen S; Lin H; Zhang Y; Li J
    Acta Pharm Sin B; 2023 Feb; 13(2):632-647. PubMed ID: 36873191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which place for avelumab in the management of urothelial carcinoma?
    Larroquette M; Gross-Goupil M; Daste A; Robert G; Ravaud A; Domblides C
    Expert Opin Biol Ther; 2019 Sep; 19(9):863-870. PubMed ID: 31286802
    [No Abstract]   [Full Text] [Related]  

  • 32. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
    Fantini M; David JM; Wong HC; Annunziata CM; Arlen PM; Tsang KY
    Cancer Biother Radiopharm; 2019 Apr; 34(3):147-159. PubMed ID: 30601063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
    Benson DM; Bakan CE; Mishra A; Hofmeister CC; Efebera Y; Becknell B; Baiocchi RA; Zhang J; Yu J; Smith MK; Greenfield CN; Porcu P; Devine SM; Rotem-Yehudar R; Lozanski G; Byrd JC; Caligiuri MA
    Blood; 2010 Sep; 116(13):2286-94. PubMed ID: 20460501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
    Watters JM; Wright G; Smith MA; Shah B; Wright KL
    Biochem Biophys Res Commun; 2021 Jan; 534():773-779. PubMed ID: 33190829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat.
    Afolabi LO; Bi J; Li X; Adeshakin AO; Adeshakin FO; Wu H; Yan D; Chen L; Wan X
    Front Immunol; 2021; 12():701671. PubMed ID: 34531855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Isoform Selectivity of HDAC Inhibitors Has a Significant Effect on PD-L1 Expression in the Triple-negative Cancer Cell Line MDA-MB-231].
    Nishino H; Hirata Y; Nagaoka Y; Uesato S
    Yakugaku Zasshi; 2022; 142(4):431-437. PubMed ID: 35370198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
    Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
    PeerJ; 2023; 11():e15922. PubMed ID: 37663280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach.
    Hoke ATK; Takahashi Y; Padget MR; Gomez J; Amit M; Burks J; Bell D; Xie T; Soon-Shiong P; Hodge JW; Hanna EY; London NR
    Transl Oncol; 2024 Jun; 44():101943. PubMed ID: 38593586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.
    Tomescu C; Tebas P; Montaner LJ
    AIDS; 2017 Mar; 31(5):613-622. PubMed ID: 28225449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 blockade enhances anti-tumor efficacy of NK cells.
    Oyer JL; Gitto SB; Altomare DA; Copik AJ
    Oncoimmunology; 2018; 7(11):e1509819. PubMed ID: 30377572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.